GEN Exclusives

More »

GEN News Highlights

More »
Aug 12, 2010

NextWave and Tris Enter into CNS Disease-Related Agreement

  • NextWave Pharmaceuticals and Tris Pharma are working together to enhance NextWave's CNS disease products with Tris’ drug-delivery technology for liquid and solid formulations. Additionally, Tris has reacquired the rights to non-CNS products including all the OTC products previously licensed to NextWave Pharmaceuticals.

    NextWave will commercialize Nexiclon™ (Clonidine) XR Extended-Release Tablets and Suspension, a 24-hour liquid extended-release product approved by the FDA; Clonidine is used to treat hypertension. The new version will be introduced to wholesalers and pharmacies later this year. NextWave and Tris will also collaborate on the development of three additional CNS products, with an option to expand development to additional products.

    All products under the agreement incorporate Tris' OralXR+ technology for delivery of suspension or solid-dosage forms, which provides up to a 24-hour delivery profile in taste-neutral formulations.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?